Lung cancer is the leading cause of cancer death worldwide. It is classified according to cell of origin into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), the latter ...
AbbVie’s antibody drug conjugate (ADC) Temab-A (telisotuzumab adizutecan) has demonstrated promising results in a Phase I trial in patients with lung cancer, as the ADC modality continues to take ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results